keyword
Keywords Kinase targeting and ovarian c...

Kinase targeting and ovarian clear cell carcinoma

https://read.qxmd.com/read/32175276/the-atypical-protein-kinase-c-small-molecule-inhibitor-%C3%AE-stat-and-its-effects-on-invasion-through-decreases-in-pkc-%C3%AE-protein-expression
#21
JOURNAL ARTICLE
Tracess Smalley, Rainer Metcalf, Rekha Patel, S M Anisul Islam, Raja Reddy Bommareddy, Mildred Acevedo-Duncan
Ovarian cancer is estimated to reach 22,530 diagnoses and cause 13,980 cancer deaths per year. The most common histology diagnosed of ovarian cancer is epithelial ovarian carcinomas (EOC). An aggressive epithelial subtype is clear cell ovarian carcinoma (CCOC) and is characterized as a non-serous ovarian cancer. Protein kinase C (PKC) is an enzymatic family of proteins that have been found to be a component in cancer progression, tissue invasion, and metastasis. The atypical PKC (aPKC) isoforms, PKC-ι and PKC-ζ, have been suggested to participate in the increased proliferation of ovarian cancers...
2020: Frontiers in Oncology
https://read.qxmd.com/read/32033228/bioinformatics-analysis-of-global-proteomic-and-phosphoproteomic-data-sets-revealed-activation-of-nek2-and-aurka-in-cancers
#22
JOURNAL ARTICLE
Barnali Deb, Pratyay Sengupta, Janani Sambath, Prashant Kumar
Tumor heterogeneity attributes substantial challenges in determining the treatment regimen. Along with the conventional treatment, such as chemotherapy and radiotherapy, targeted therapy has greater impact in cancer management. Owing to the recent advancements in proteomics, we aimed to mine and re-interrogate the Clinical Proteomic Tumor Analysis Consortium (CPTAC) data sets which contain deep scale, mass spectrometry (MS)-based proteomic and phosphoproteomic data sets conducted on human tumor samples. Quantitative proteomic and phosphoproteomic data sets of tumor samples were explored and downloaded from the CPTAC database for six different cancers types (breast cancer, clear cell renal cell carcinoma (CCRCC), colon cancer, lung adenocarcinoma (LUAD), ovarian cancer, and uterine corpus endometrial carcinoma (UCEC))...
February 4, 2020: Biomolecules
https://read.qxmd.com/read/31719920/dual-inhibitors-loaded-nanotherapeutics-that-target-kinase-signaling-pathways-synergize-with-immune-checkpoint-inhibitor
#23
JOURNAL ARTICLE
Anujan Ramesh, Siva Kumar Natarajan, Dipika Nandi, Ashish Kulkarni
INTRODUCTION: Immune checkpoint inhibitors that boost cytotoxic T cell-based immune responses have emerged as one of the most promising approaches in cancer treatment. However, it is increasingly being realized that T cell activation needs to be rationally combined with molecularly targeted therapeutics for a maximal anti-tumor outcome. Currently, two oncogenic drivers, MAPK and PI3K-mTOR have emerged as the two main molecular targets for combining with immunotherapy. However, there are major challenges in enabling such combinations: first, such combinations can result in high rates of toxicity...
October 2019: Cellular and Molecular Bioengineering
https://read.qxmd.com/read/31493899/anti-tumor-activity-of-dual-inhibition-of-phosphatidylinositol-3-kinase-and-mdm2-against-clear-cell-ovarian-carcinoma
#24
JOURNAL ARTICLE
Chinami Makii, Yuji Ikeda, Katsutoshi Oda, Yuriko Uehara, Akira Nishijima, Takahiro Koso, Yoshiko Kawata, Tomoko Kashiyama, Aki Miyasaka, Kenbun Sone, Michihiro Tanikawa, Tetsushi Tsuruga, Mayuyo Mori-Uchino, Kazunori Nagasaka, Yoko Matsumoto, Osamu Wada-Hiraike, Kei Kawana, Kosei Hasegawa, Keiichi Fujiwara, Hiroyuki Aburatani, Yutaka Osuga, Tomoyuki Fujii
INTRODUCTION: PI3K pathway signaling has received attention as a molecular target in clear cell ovarian carcinoma (CCOC). MDM2 is one of the AKT effectors in the PI3K pathway, which binds to and degrades p53. In this study, we aimed to clarify the prognostic significance of PIK3CA and MDM2 expression, and potential therapeutic effect of a dual inhibition of the PI3K pathway and MDM2. MATERIALS AND METHODS: cDNA expression was evaluated by using microarray data using 75 samples of CCOC...
November 2019: Gynecologic Oncology
https://read.qxmd.com/read/31461811/-expression-and-significance-of-mapk-erk-in-the-specimens-and-cells-of-epithelial-ovarian-cancer
#25
JOURNAL ARTICLE
X L Jiang, J C Gao, L Jiang, P X Zhang, T J Kang, Q Sun, W J Qi, Q P Zhang, H W Guan, H Shi
Objective: To detect phosphorylated-extracellular signal-regulated kinase (p-ERK1/2) protein expression in epithelial ovarian cancer and cell lines, and to examine the effects of mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor AZD6244 on cell proliferation, apoptosis as well as cell cycle of ovarian cancer cells. To explore the function and significance of MAPK/extracellular signal-regulated kinase (ERK) signaling pathway in the development of ovarian cancer. Methods: (1) A total of 104 cases of patients with ovarian cancer who accepted the treatment of gynecological surgery and being confirmed by pathological examination in First Affiliated Hospital, Dalian Medical University from January 2004 to December 2013 were selected...
August 25, 2019: Zhonghua Fu Chan Ke za Zhi
https://read.qxmd.com/read/31366141/current-position-of-the-molecular-therapeutic-targets-for-ovarian-clear-cell-carcinoma-a-literature-review
#26
REVIEW
Tsukuru Amano, Tokuhiro Chano, Fumi Yoshino, Fuminori Kimura, Takashi Murakami
Ovarian clear cell carcinoma (OCCC) shows low sensitivity to conventional chemotherapy and has a poor prognosis, especially in advanced stages. Therefore, the development of innovative therapeutic strategies and precision medicine for the treatment of OCCC are important. Recently, several new molecular targets have been identified for OCCC, which can be broadly divided into four categories: a) downstream pathways of receptor tyrosine kinases, b) anti-oxidative stress molecules, c) AT-rich interactive domain 1A-related chromatin remodeling errors, and d) anti-programmed death ligand 1/programmed cell death 1 agents...
July 30, 2019: Healthcare (Basel, Switzerland)
https://read.qxmd.com/read/31319139/low-dose-triple-drug-combination-targeting-the-pi3k-akt-mtor-pathway-and-the-mapk-pathway-is-an-effective-approach-in-ovarian-clear-cell-carcinoma
#27
JOURNAL ARTICLE
Joseph J Caumanns, Anne van Wijngaarden, Arjan Kol, Gert J Meersma, Mathilde Jalving, René Bernards, Ate G J van der Zee, G Bea A Wisman, Steven de Jong
Advanced stage ovarian clear cell carcinoma (OCCC) is poorly responsive to platinum-based chemotherapy and has an unfavorable prognosis. Previous studies revealed heterogeneous mutations in PI3K/AKT/mTOR and MAPK pathway nodules converging in mTORC1/2 activation. Here, we aimed to identify an effective low-dose combination of PI3K/AKT/mTOR pathway and MAPK pathway inhibitors simultaneously targeting key kinases in OCCC to preclude single-inhibitor initiated pathway rewiring and limit toxicity. Small molecule inhibitors of mTORC1/2, PI3K and MEK1/2 were combined at monotherapy IC20 doses in a panel of genetically diverse OCCC cell lines (n=7) to determine an optimal low-dose combination...
July 15, 2019: Cancer Letters
https://read.qxmd.com/read/30542723/mir%C3%A2-381-regulates-cell-motility-growth-and-colony-formation-through-pik3ca-in-endometriosis%C3%A2-associated-clear-cell-and-endometrioid-ovarian-cancer
#28
JOURNAL ARTICLE
Chia-Yi Hsu, Tsung-Hua Hsieh, Tze-Kiong Er, Hung-Sheng Chen, Ching-Chou Tsai, Eing-Mei Tsai
Ovarian cancer is the one of the most lethal gynecological cancer types. MicroRNAs (miRs) are noncoding RNAs that modulate the translation of their target mRNAs via binding to a complementary sequence in the target 3' untranslated region, and the dysregulation of certain miRs has been demonstrated to contribute to cancer progression. In this regard, the current study extended our previous work and used next‑generation sequencing data to search for upstream regulators of genetic alterations that are common in ovarian cancer, as well as the miRs that are involved in controlling the expression of these regulators...
October 9, 2018: Oncology Reports
https://read.qxmd.com/read/30186750/death-receptor-6-promotes-ovarian-cancer-cell-migration-through-kif11
#29
JOURNAL ARTICLE
Bianhua Shi, Jiayu Bao, Yongbin Liu, Juan Shi
The expression of death receptor 6 (DR6) is abnormal in some cancer types, but the function and underlying molecular mechanisms of DR6 in tumor progression are not yet clear. In the present study, our analysis of ovarian cancer RNA sequencing data from The Cancer Genome Atlas revealed that DR6 is upregulated in human ovarian cancer. We confirmed that the expression level of DR6 is upregulated in ovarian cancer tissues when compared with matched adjacent normal tissues. In addition, DR6 enhanced ovarian carcinoma cell migration ability, and decreased expression of DR6 inhibited the expression of matrix metalloprotease (MMP) 2 and MMP9, and increased the expression of E-cadherin...
September 2018: FEBS Open Bio
https://read.qxmd.com/read/30108107/a-clinical-and-molecular-phase-ii-trial-of-oral-enmd-2076-in-ovarian-clear-cell-carcinoma-occc-a-study-of-the-princess-margaret-phase-ii-consortium
#30
JOURNAL ARTICLE
Stephanie Lheureux, Anna V Tinker, Blaise A Clarke, Prafull Ghatage, Stephen Welch, Johanne I Weberpals, Neesha C Dhani, Marcus O Butler, Katia Tonkin, Qian Tan, David S P Tan, Kelly Brooks, Janelle Ramsahai, Lisa Wang, Nhu-An Pham, Patricia A Shaw, Ming-Sound Tsao, Swati Garg, Tracy L Stockley, Amit M Oza
PURPOSE: Patients with recurrent ovarian clear cell carcinoma (OCCC) have limited effective options due to chemo-resistance. A phase II study was designed to assess the activity of ENMD-2076, an oral multi-target kinase selective against Aurora-A and VEGFR. EXPERIMENTAL DESIGN: This multi-center Phase II study included patients with recurrent OCCC who received prior platinum-based chemotherapy. Primary endpoints were objective response and 6-month progression free survival (PFS) rates...
August 14, 2018: Clinical Cancer Research
https://read.qxmd.com/read/29707125/the-hnf-1%C3%AE-usp28-claspin-pathway-upregulates-dna-damage-induced-chk1-activation-in-ovarian-clear-cell-carcinoma
#31
JOURNAL ARTICLE
Fuminori Ito, Chiharu Yoshimoto, Yuki Yamada, Tamotsu Sudo, Hiroshi Kobayashi
Transcription factor hepatocyte nuclear factor 1-beta (HNF-1β) enhances checkpoint kinase 1 (Chk1) activation and promotes G2/M cell cycle progression in ovarian clear cell carcinoma (CCC) following exposure to diverse genotoxic agents including bleomycin. However, the underlying mechanism leading to checkpoint activation of HNF-1β still remains largely unknown. To clarify the effects of HNF-1β on cell cycle checkpoints, human CCC cell lines were transfected with siRNAs targeting HNF-1β, Claspin , USP28, or a control vector...
April 3, 2018: Oncotarget
https://read.qxmd.com/read/29685880/integrative-kinome-profiling-identifies-mtorc1-2-inhibition-as-treatment-strategy-in-ovarian-clear-cell-carcinoma
#32
JOURNAL ARTICLE
Joseph J Caumanns, Katrien Berns, G Bea A Wisman, Rudolf S N Fehrmann, Tushar Tomar, Harry Klip, Gert J Meersma, E Marielle Hijmans, Annemiek M C Gennissen, Evelien W Duiker, Desiree Weening, Hiroaki Itamochi, Roelof J C Kluin, Anna K L Reyners, Michael J Birrer, Helga B Salvesen, Ignace Vergote, Els van Nieuwenhuysen, James Brenton, E Ioana Braicu, Jolanta Kupryjanczyk, Beata Spiewankiewicz, Lorenza Mittempergher, René Bernards, Ate G J van der Zee, Steven de Jong
Purpose: Advanced-stage ovarian clear cell carcinoma (OCCC) is unresponsive to conventional platinum-based chemotherapy. Frequent alterations in OCCC include deleterious mutations in the tumor suppressor ARID1A and activating mutations in the PI3K subunit PIK3CA In this study, we aimed to identify currently unknown mutated kinases in patients with OCCC and test druggability of downstream affected pathways in OCCC models. Experimental Design: In a large set of patients with OCCC ( n = 124), the human kinome (518 kinases) and additional cancer-related genes were sequenced, and copy-number alterations were determined...
August 15, 2018: Clinical Cancer Research
https://read.qxmd.com/read/29663364/impact-of-iaspp-on-chemoresistance-through-plk1-and-autophagy-in-ovarian-clear-cell-carcinoma
#33
JOURNAL ARTICLE
Ka-Kui Chan, Oscar Gee-Wan Wong, Esther Shuk-Ying Wong, Karen Kar-Loen Chan, Philip Pun-Ching Ip, Ka-Yu Tse, Annie Nga-Yin Cheung
Ovarian clear cell carcinoma (OCCC) is a type of epithelial ovarian cancer that is strongly associated with endometriosis, resistance against conventional chemotherapy and thus poorer prognosis. The expression of inhibitory member of the ASPP family proteins (iASPP) and Polo-like kinase (PLK)1 were significantly higher in OCCC compared to benign cystadenomas and endometriosis. Both protein expressions were found to correlate with chemoresistance in patients with OCCC while high iASPP expression alone was significantly associated with a poor patient survival...
September 15, 2018: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/29645088/impact-of-iaspp-on-chemoresistance-through-plk1-and-autophagy-in-ovarian-clear-cell-carcinoma
#34
JOURNAL ARTICLE
Ka-Kui Chan, Oscar Gee-Wan Wong, Esther Shuk-Ying Wong, Karen Kar-Loen Chan, Philip Pun-Ching Ip, Ka-Yu Tse, Annie Nga-Yin Cheung
Ovarian clear cell carcinoma (OCCC) is a type of epithelial ovarian cancer that is strongly associated with endometriosis, resistance against conventional chemotherapy and thus poorer prognosis. The expression of inhibitory member of the ASPP family proteins (iASPP) and Polo-like kinase (PLK)1 were significantly higher in OCCC compared to benign cystadenomas and endometriosis. Both protein expressions were found to correlate with chemoresistance in patients with OCCC while high iASPP expression alone was significantly associated with a poor patient survival...
April 12, 2018: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/29325268/-clinical-significance-of-targeting-drug-based-molecular-biomarkers-expression-in-ovarian-clear-cell-carcinoma
#35
JOURNAL ARTICLE
M J Li, H R Li, X Cheng, R Bi, X Y Tu, F Liu, L H Chen
Objective: To assess the expression level of targeting drug-based molecular biomarkers in ovarian clear cell carcinoma (OCCC) tissues and its clinical significance. Methods: A total of 63 OCCC patients included 40 primary OCCC and 23 recurrent OCCC for secondary cytoreductive surgery (SCS), who had received primary surgeries at Fudan University Shanghai Cancer Center between January, 2008 and December, 2015 were enrolled, and immunohistochemistry SP method was used to test human epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-2 (HER2), aurora kinase A (AURKA), breast cancer susceptibility gene 1 (BRCA1), BRCA2 and programmed death-ligand 1 (PD-L1)protein expression in paraffin-embedded tissues...
December 25, 2017: Zhonghua Fu Chan Ke za Zhi
https://read.qxmd.com/read/29061793/the-anti-tumor-effect-of-cabozantinib-on-ovarian-clear-cell-carcinoma-in-vitro-and-in-vivo
#36
JOURNAL ARTICLE
Makiko Nakatani, Hidemichi Watari, Takashi Mitamura, Lei Wang, Yutaka Hatanaka, Kanako C Hatanaka, Kohei Honda, Toshiyuki Nomura, Hiroshi Nishihara, Shinya Tanaka, Noriaki Sakuragi
BACKGROUND: Several reports have shown that the overexpression of the MET proto-oncogene, receptor tyrosine kinase (MET), was more frequently observed in clear cell carcinoma (CCC) than in non-CCC. We evaluated the antitumor activity of cabozantinib, that targets MET. MATERIALS AND METHODS: A gene expression analysis of tumors from human ovarian cancers was carried out by transcriptome sequencing. An in vitro 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide assay (MTT assay) and in vivo experiments were performed to determine the activity of cabozantinib...
November 2017: Anticancer Research
https://read.qxmd.com/read/28728166/whole-genome-sequencing-revealed-novel-prognostic-biomarkers-and-promising-targets-for-therapy-of-ovarian-clear-cell-carcinoma
#37
JOURNAL ARTICLE
Hiroaki Itamochi, Tetsuro Oishi, Nao Oumi, Satoshi Takeuchi, Kosuke Yoshihara, Mikio Mikami, Nobuo Yaegashi, Yasuhisa Terao, Kazuhiro Takehara, Kimio Ushijima, Hidemichi Watari, Daisuke Aoki, Tadashi Kimura, Toshiaki Nakamura, Yoshihito Yokoyama, Junzo Kigawa, Toru Sugiyama
BACKGROUND: Ovarian clear cell carcinoma (OCCC) is mostly resistant to standard chemotherapy that results in poor patient survival. To understand the genetic background of these tumours, we performed whole-genome sequencing of OCCC tumours. METHODS: Tumour tissue samples and matched blood samples were obtained from 55 Japanese women diagnosed with OCCC. Whole-genome sequencing was performed using the Illumina HiSeq platform according to standard protocols. RESULTS: Alterations to the switch/sucrose non-fermentable (SWI/SNF) subunit, the phosphatidylinositol-3-kinase (PI3K)/Akt signalling pathway, and the receptor tyrosine kinase (RTK)/Ras signalling pathway were found in 51%, 42%, and 29% of OCCC tumours, respectively...
August 22, 2017: British Journal of Cancer
https://read.qxmd.com/read/28652252/glycerol-3-phosphate-acyltransferase-1-promotes-tumor-cell-migration-and-poor-survival-in-ovarian-carcinoma
#38
JOURNAL ARTICLE
Rosemarie Marchan, Bettina Büttner, Jörg Lambert, Karolina Edlund, Iris Glaeser, Meinolf Blaszkewicz, Gregor Leonhardt, Lisa Marienhoff, Darius Kaszta, Moritz Anft, Carsten Watzl, Katrin Madjar, Marianna Grinberg, Eugen Rempel, Roland Hergenröder, Silvia Selinski, Jörg Rahnenführer, Michaela S Lesjak, Joanna D Stewart, Cristina Cadenas, Jan G Hengstler
Glycerophosphodiesterase EDI3 (GPCPD1; GDE5; GDPD6) has been suggested to promote cell migration, adhesion, and spreading, but its mechanisms of action remain uncertain. In this study, we targeted the glycerol-3-phosphate acyltransferase GPAM along with choline kinase-α (CHKA), the enzymes that catabolize the products of EDI3 to determine which downstream pathway is relevant for migration. Our results clearly showed that GPAM influenced cell migration via the signaling lipid lysophosphatidic acid (LPA), linking it with GPAM to cell migration...
September 1, 2017: Cancer Research
https://read.qxmd.com/read/28454214/genome-wide-analysis-of-gynecologic-cancer-the-cancer-genome-atlas-in-ovarian-and-endometrial-cancer
#39
JOURNAL ARTICLE
Moito Iijima, Kouji Banno, Ryuichiro Okawa, Megumi Yanokura, Miho Iida, Takashi Takeda, Haruko Kunitomi-Irie, Masataka Adachi, Kanako Nakamura, Kiyoko Umene, Yuya Nogami, Kenta Masuda, Eiichiro Tominaga, Daisuke Aoki
Cancer typically develops due to genetic abnormalities, but a single gene abnormality cannot completely account for the onset of cancer. The Cancer Genome Atlas (CGA) project was conducted for the cross-sectional genome-wide analysis of numerous genetic abnormalities in various types of cancer. This approach has facilitated the identification of novel AT-rich interaction domain 1A gene mutations in ovarian clear cell carcinoma, frequent tumor protein 53 (TP53) gene mutations in high-grade ovarian serous carcinoma, and Kirsten rat sarcoma and B-rapidly accelerated fibrosarcoma proto-oncogene, serine/threonine kinase gene mutations in low-grade ovarian serous carcinoma...
March 2017: Oncology Letters
https://read.qxmd.com/read/28259988/targeting-glutamine-metabolism-and-the-focal-adhesion-kinase-additively-inhibits-the-mammalian-target-of-the-rapamycin-pathway-in-spheroid-cancer-stem-like-properties-of-ovarian-clear-cell-carcinoma-in%C3%A2-vitro
#40
JOURNAL ARTICLE
Masakazu Sato, Kei Kawana, Katsuyuki Adachi, Asaha Fujimoto, Mitsuyo Yoshida, Hiroe Nakamura, Haruka Nishida, Tomoko Inoue, Ayumi Taguchi, Juri Ogishima, Satoko Eguchi, Aki Yamashita, Kensuke Tomio, Osamu Wada-Hiraike, Katsutoshi Oda, Takeshi Nagamatsu, Yutaka Osuga, Tomoyuki Fujii
Ovarian cancer is one of the leading causes of death in the world, which is linked to its resistance to chemotherapy. Strategies to overcome chemoresistance have been keenly investigated. Culturing cancer cells in suspension, which results in formation of spheroids, is a more accurate reflection of clinical cancer behavior in vitro than conventional adherent cultures. By performing RNA-seq analysis, we found that the focal adhesion pathway was essential in spheroids. The phosphorylation of focal adhesion kinase (FAK) was increased in spheroids compared to adherent cells, and inhibition of FAK in spheroids resulted in inhibition of the downstream mammalian target of the rapamycin (mTOR) pathway in ovarian clear cell carcinomas...
April 2017: International Journal of Oncology
keyword
keyword
72421
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.